This is a routine investor presentation filing with no new material information. Monitor for future filings containing clinical updates, financial results, or financing activities for trading catalysts.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $3.49entry
- T+1 · 2mo ago −2.58%α −2.12% · $3.40
- T+5 · 8w ago −5.73%α −5.84% · $3.29
- T+20 · 5w ago −18.34%α −20.60% · $2.85
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors and analysts on September 8, 2026. The filing is a routine Regulation FD disclosure with no new material financial data, guidance, or corporate events. The presentation content was not extractable from the provided documents, limiting analysis to the filing's procedural nature.
Key Facts
- NRX Pharmaceuticals filed an 8-K on September 14, 2026, regarding Item 7.01 Regulation FD Disclosure.
- The filing furnishes an investor presentation (Exhibit 99.1) used in meetings on September 8, 2026.
- No financial results, guidance, or material corporate events were disclosed in the 8-K body.
- The investor presentation content was not available for analysis.
Financial Impact
Not specified
Risk Factors
- No material financial or operational data disclosed; stock movement may be driven by unstated market expectations.
- Investor presentation content was unavailable, limiting insight into management's messaging.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030228 |
| Document: 0001437749-26-030228-index-headers.html | 0001437749-26-030228 |
| Document: 0001437749-26-030228-index.html | 0001437749-26-030228 |
| Document: 0001437749-26-030228.txt | 0001437749-26-030228 |
Track record
22 reports on NRXP
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Viewing Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers